Kano Therapeutics
Cambridge, US · Founded 2021 · Delaware corporation · 6 known investors
Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA. It manufactures cssDNA via industrial fermentation and licenses and supplies the payload to therapeutic developers through integrated partnerships spanning discovery to GMP.
BiotechDeep Tech
Founders & leadership
FE
Floris EngelhardtNamed on SEC filing
JV
John VroomNamed on SEC filing
Board
AD
Investors · 6
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2024
▶$5MraisedMay 2024 · 4 investors · BiotechnologyRule 506(b)
▶$5MraisedMay 2024 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ann DeWittDirector
- Floris EngelhardtExecutive Officer, Director
- John VroomDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapKenaitx11 shared keywordsKenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for neurological conditions such as Parkinson's disease. Its lead program, RNDP-001, is being evaluated in the REPLACE Phase 1b/2a clinical trial for idiopathic Parkinson's disease.
Bioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Transcode Therapeutics7 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
Day One Biopharmaceuticals6 shared keywordsDay One Biopharmaceuticals is an oncology drug developer that pursues a "search and development" strategy to bring targeted cancer medicines to patients of all ages, with a focus on pediatric low-grade glioma (pLGG). The company is part of Servier.
Companies competing with Kano Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Kano Therapeutics do?
- Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA. It manufactures cssDNA via industrial fermentation and licenses and supplies the payload to therapeutic developers through integrated partnerships spanning discovery to GMP.
- Who are Kano Therapeutics's investors?
- Kano Therapeutics's investors include Fifty Years, Launchpad Venture Group, Metaplanet, The Engine Ventures, Vsquared Ventures, ZAKA VC.
- How much funding has Kano Therapeutics raised?
- Kano Therapeutics has disclosed $5M raised across 1 round.
- Where is Kano Therapeutics headquartered?
- Kano Therapeutics is headquartered in Cambridge, US.